京新药业(002020) - 2015 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2015 was ¥331,331,626.09, representing a 21.40% increase compared to ¥272,928,143.87 in the same period last year[8] - Net profit attributable to shareholders was ¥41,010,023.68, a significant increase of 66.12% from ¥24,687,096.21 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥39,781,586.23, up 59.11% from ¥25,002,655.06 in the previous year[8] - The net cash flow from operating activities reached ¥95,580,596.04, marking a 26.32% increase from ¥75,668,082.70 in the same quarter last year[8] - Basic earnings per share rose to ¥0.1432, a 46.57% increase compared to ¥0.0977 in the previous year[8] - Operating profit increased by 61.76% to ¥47,088,103.20, driven by growth in main business revenue[18] - Total profit rose by 68.90% to ¥48,537,936.09, mainly due to the increase in operating profit[18] - Net profit increased by 66.12% to ¥41,010,023.68, reflecting the growth in operating profit[18] - The company expects net profit attributable to shareholders for the first half of 2015 to increase by 50.00% to 80.00%, ranging from ¥8,925 to ¥10,710[21] Assets and Shareholder Information - Total assets at the end of the reporting period were ¥2,143,937,432.10, reflecting a 3.84% increase from ¥2,064,659,374.11 at the end of the previous year[8] - Net assets attributable to shareholders increased to ¥1,439,548,425.24, up 2.93% from ¥1,398,538,401.56 at the end of the last fiscal year[8] - The total number of ordinary shareholders at the end of the reporting period was 14,712[11] - The largest shareholder, Lü Gang, holds 21.08% of the shares, amounting to 60,384,440 shares, with 45,288,330 shares pledged[11] Changes in Financial Metrics - The weighted average return on net assets was 2.89%, a slight decrease of 0.08 percentage points from 2.97% in the previous year[8] - Prepayments increased by 35.18% to ¥7,199,566.45, primarily due to an increase in advance payments for materials[15] - Other receivables rose by 81.75% to ¥18,827,517.54, mainly due to an increase in personal loans[16] - Construction in progress increased by 36.44% to ¥33,176,943.04, attributed to increased payments for fundraising projects[16] - Short-term borrowings decreased by 54.61% to ¥17,772,638.92, primarily due to loan repayments[16] Expenses - Sales expenses increased by 30.64% to ¥76,269,880.87, mainly due to increased business expenses from higher revenue[16] - Management expenses rose by 32.36% to ¥38,976,266.56, primarily due to increased technical development costs[16]